Phase 1 Secondary Progressive Multiple Sclerosis Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis

Queen Mary University of London72 enrolled1 locationNCT03783416

Completed

Phase 1

Open-label study to assess how the pharmacokinetics (i.e. the way the body absorbs, distributes and gets rid of a drug), safety, and tolerability of the drug siponimod are influenced by the presence of specific genetic characteristics (namely CYP2C9 genotypes).

The medical condition pursued for siponimod is Secondary Progressive Multiple Sclerosis (SPMS). This study aims to characterize the PK profile of siponimod in healthy subjects with the CYP2C9 extensive and poor metabolizer phenotype.

Novartis Pharmaceuticals Australia Pty Limited24 enrolled3 locationsACTRN12613000545763